Efficacy and Tolerability of Xalatan in Patients

CompletedOBSERVATIONAL

Enrollment

1,289

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

Xalatan 0.005% eye drops

ophthalmic solution dosed once daily for 3 months

Trial Locations (3)

Pfizer Investigational Site, Alexandria

Pfizer Investigational Site, Jeddah

Pfizer Investigational Site, Umm Al Quwain City

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00950690 - Efficacy and Tolerability of Xalatan in Patients | Biotech Hunter | Biotech Hunter